The mechanism of action of ZILXI for the treatment of inflammatory lesions of rosacea is unknown.

ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults.

Topical foam, 1.5%. The topical foam should be applied at approximately the same time each day at least 1 hour before bedtime. The patient should not bathe, shower or swim for at least 1 hour after application of the product.

The most common adverse reaction reported by ≥1% of subjects treated with ZILXI and more frequently than in subjects treated with vehicle was diarrhea (1% vs. 0%), respectively. (See Full Prescribing Information.)

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any other ingredients in ZILXI.

The propellant in ZILXI is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C). Other precautions were listed at Teratogenic Effects, Tooth Discoloration, Inhibition of Bone Growth, Clostridioides difficile Associated Diarrhea, Hepatotoxicity, Metabolic Effects, Central Nervous System Effects, Intracranial Hypertension, Autoimmune Syndromes, Photosensitivity, Serious Skin/Hypersensitivity Reaction, Tissue Hyperpigmentation, Development of Drug-Resistant Bacteria, Superinfection/Potential for Microbial Overgrowth. (See Full Prescribing Information.)